Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry

被引：0
|
作者：
Rasmussen, Sean [1 ,2 ]
Taylor, Valerie [2 ]
Surette, Alexi [3 ]
Barnes, Penny [1 ,2 ]
Bethune, Gillian [1 ,2 ]
机构：
[1] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[2] Dalhousie Univ, Halifax, NS, Canada
[3] Vitalite Hlth Network, Moncton, NB, Canada
来源：
MODERN PATHOLOGY | 2022年 / 35卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
164
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [1] Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry
    Rasmussen, Sean
    Taylor, Valerie
    Surette, Alexi
    Barnes, Penny
    Bethune, Gillian
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 182 - 182
  • [2] Using Deep Learning to Predict Final HER2 Status in Invasive Breast Cancers That are Equivocal (2+) by Immunohistochemistry
    Rasmussen, Sean A. A.
    Taylor, Valerie J.
    Surette, Alexi P.
    Barnes, Penny J.
    Bethune, Gillian C.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2022, 30 (10) : 668 - 673
  • [3] Correlation of immunohistochemistry-equivocal (2+) human epidermal growth factor receptor 2 (HER2) with fluorescence in situ hybridization (FISH) gene status in invasive breast cancer: Is FISH necessary for all HER2 equivocal breast cancer cases?
    Alswayyed, Mohammed
    KUWAIT MEDICAL JOURNAL, 2022, 54 (04): : 476 - 480
  • [4] Percentage of Her2 positive cells in immunohistochemistry-equivocal (2+) invasive breast cancer and its significance as a predictive value for the amplification status
    Marras, V.
    Satta, G.
    Fedeli, M. A.
    Trombetta, M.
    Lako, K.
    Meloni, M.
    Fara, A. M.
    Camboni, A. C.
    Doneddu, V.
    Manca, A.
    Tanda, F.
    VIRCHOWS ARCHIV, 2017, 471 : S58 - S58
  • [5] Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer
    Ji, Yongling
    Sheng, Liming
    Du, Xianghui
    Qiu, Guoqin
    Chen, Bo
    Wang, Xiaojia
    JOURNAL OF THORACIC DISEASE, 2014, 6 (07) : 896 - 904
  • [6] Biological analysis of HER2 equivocal (2+) cases in primary breast cancer.
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Nakano, Masahiro
    Fujisue, Mamiko
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] The role of HER2 gene copy number variations in immunohistochemistry-equivocal (2+) breast cancer
    Kocsmar, I.
    Tokes, A. M.
    Kafer, D.
    Kocsmar, E.
    Kristof, K. Attila
    Kulka, J.
    Lotz, G.
    VIRCHOWS ARCHIV, 2020, 477 : S225 - S225
  • [8] Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry
    Valerie J. Taylor
    Penny J. Barnes
    Sean C. Godwin
    Gillian C. Bethune
    Virchows Archiv, 2021, 479 : 23 - 31
  • [9] Predicting factor for HER-2 gene status in immunohistochemistry-equivocal (2+) breast cancer
    Kim, S. K.
    Kang, S. Y.
    Youn, H. J.
    Jung, S. H.
    BREAST, 2015, 24 : S62 - S62
  • [10] Resolving the ERBB2 (HER2) Status of Invasive Breast Cancers with Double-Equivocal HER2 Status by Immunohistochemistry and Fluorescence In-situ Hybridization
    Hon, Jane Date
    Zhang, Xinmin
    Edmonston, Tina Bocker
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146 : S96 - S96
12345